The acute on chronic liver failure (ACLF) market includes drugs and therapies used to treat patients with acute deterioration of known or unknown chronic liver diseases leading to organ failures and increased mortality. ACLF requires emergency care and monitoring in intensive care units. It is characterized by jaundice, ascites, hepatic encephalopathy and coagulopathy. The leading causes of ACLF include alcohol abuse, viral hepatitis, non-alcoholic steatohepatitis and autoimmune liver diseases. Drugs used to treat ACLF include antibiotics, glucocorticoids, pentoxifylline, N-acetyl cysteine, artificial liver support systems and liver transplants. The global ACLF market is mainly driven by increasing alcohol consumption, growing prevalence of viral hepatitis and non-alcoholic fatty liver disease leading to chronic liver diseases.

The Global Acute on Chronic Liver Failure Market is estimated to be valued at US$ 4.2 Bn in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024-2031.

Key Takeaways
Key players operating in the ACLF market are Promethera Biosciences, Beijing Continent Pharmaceutical Co, Ltd, Cellaion SA, Versantis, Novartis. Promethera Biosciences is developing HepaStem, a cell-based therapy for ACLF patients.

The growing prevalence of chronic liver diseases such as alcohol-related liver disease, non-alcoholic fatty liver disease and viral hepatitis has fuelled the demand for ACLF treatment. According to the Global Burden of Disease Study, viral hepatitis caused 1.34 million deaths in 2020.

Major pharmaceutical companies are expanding their ACLF portfolio through acquisitions and partnerships. In 2021, Novartis acquired Signifys pharmaceuticals to accelerate development of therapies for ACLF and related conditions.

Market drivers
Increasing alcohol consumption is a major driver for ACLF market. Excessive and long-term alcohol use leads to alcoholic liver disease and liver cirrhosis, which are the most common causes of ACLF. According to WHO, around 3 million deaths every year result from the harmful use of alcohol. This includes deaths from liver cirrhosis and ACLF triggered by alcohol abuse. The rising global alcohol consumption is expected to significantly drive market growth during forecast period.

Impact of geopolitical situation on ACLF market growth

The acute on chronic liver failure (ACLF) market is facing headwinds due to the geopolitical tensions caused by the Russia-Ukraine war and global economic slowdown. The Russia-Ukraine conflict has disrupted global supply chains, increased costs of raw materials and logistics, resulting in price hikes of ACLF drugs and therapies. This is negatively impacting the growth prospects of the ACLF market. Additionally, deteriorating macroeconomic conditions and high inflation rates across major world economies like the US and Europe has reduced healthcare spending power. This is impacting the demand for expensive ACLF treatments.

To offset these challenges, ACLF market players need to focus on strengthening their supply chain resilience by diversifying and developing alternative supplier networks. Companies should look at nearshoring or onshoring drug manufacturing to key markets to reduce dependency on single regions. Additionally, partnerships with regional healthcare providers, lowering drug prices through value-based care models and developing affordable therapies specific to low and middle-income countries could help drive future market growth.

Geographical regions with high ACLF market value

The ACLF market in terms of value is largely concentrated in North America and Western Europe. This is due to high diagnosis and treatment rates in the US and major Western European countries. According to estimates, North America accounted for over 35% of the global ACLF market value in 2024 due to large healthcare expenditure and accessibility of advanced ACLF therapies in the region. Meanwhile, countries like Germany, United Kingdom and France constitute over 25% of the European ACLF market value. This is attributed to established universal healthcare coverage and accessibility to novel drug therapies in these nations.

Fastest growing region for ACLF market

The Asia Pacific region excluding Japan is predicted to be the fastest growing market for ACLF over the forecast period till 2031. This is owing to rising prevalence of chronic liver diseases like alcohol-related liver disorder and viral hepatitis in developing Asian nations. According to WHO, China and India account for over 35% of global viral hepatitis cases. Additionally, improving healthcare infrastructure, increasing healthcare spending, large patient pools and growing medical tourism are supporting the ACLF market growth in the Asia Pacific region. ACLF drug makers are also focusing on collaborating with local clinical sites and healthcare providers to boost regional market presence.

Get more insight on this topic :

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc